Biotech startup wants to make new short-acting psychedelic drugs more scalable & accessible

April 20, 2020 Articles 7:21 pm

As the mental health benefits of the magic mushroom-derived drug psilocybin become more mainstream, researchers and developers are looking for ways to make new drugs more accessible for clinical therapy.

 

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit